Can a common blood pressure pill fight prostate cancer?

NCT ID NCT06168487

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This early-phase trial is investigating whether telmisartan, a drug typically used for high blood pressure, can be safely given to men with prostate cancer — either alone or alongside standard chemotherapy. Researchers will also look for signs that the drug damages tumor DNA or boosts the immune system's ability to attack cancer cells. The study enrolls 36 adults with prostate cancer who do not need an immediate change in their current treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
telmisartan, a blood pressure drug also known as Micardis, given alone or with standard chemotherapy
What this could lead to
If telmisartan proves tolerable and shows signs of anti-tumor activity, it could point toward a new, repurposed treatment option for prostate cancer.
What could go wrong
This is a very early phase 1 trial with only 36 participants, focused primarily on safety. It is not designed to prove effectiveness, and telmisartan may not meaningfully impact cancer growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dartmouth Health

    RECRUITING

    Lebanon, New Hampshire, 03756, United States

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.